Developer docs
API playgroundTry for free, no card

Search company profiles

Triastek

Full company profile

uuid0000mzx

Namestring
Triastek
Legal namestring
Triastek, Inc.
Websiteurl
triastek.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Triastek, Inc. is a privately held Chinese pharmaceutical technology company founded in July 2015 and headquartered in Nanjing, Jiangsu, with additional offices in Shanghai and a GMP-compliant production facility in Nanjing. The company developed and commercializes the proprietary Melt Extrusion Deposition (MED®) 3D printing process, an additive manufacturing technology that continuously converts powder feedstocks into softened or molten states and deposits them layer-by-layer to produce solid oral dosage forms with engineered 3D geometric structures. MED® operates across a 25–250°C temperature range, supports more than 200 pharmaceutical excipients and 1,000+ compositions, and integrates Process Analytical Technology (PAT) for real-time, per-tablet quality control. The platform is complemented by a family of five specialized 3D Microstructure delivery technology platforms (3DμS®-IT, -MR, -GR, -SE, -OM) and two hybrid processes (MED&MIM for gastric retention, MED&SSE for peptides), as well as the 3DFbD® digital formulation-by-design methodology.

The company operates a dual business model. In its Product Partnership model, Triastek internally develops proprietary 3D-printed drug candidates (T19, T20, T20G, T21, T24, T25, T26, D23) through FDA 505(b)(1)/(b)(2) and NMPA pathways and out-licenses global commercialization rights for upfront fees, development milestones, and royalties. In its Technology Platform Partnership model, it provides MED® platform access, research collaboration, and co-development services to global pharmaceutical companies; named partners include Eli Lilly, Boehringer Ingelheim, BioNTech, Merck KGaA (MilliporeSigma), Siemens, and Sperogenix. Revenue is generated through research fees, milestone payments, technology access fees, and licensing royalties. The company holds 152 patent applications and 117 granted patents across 12 territories, representing more than 20% of global 3D printing pharmaceutical patent applications, and was the first Chinese pharmaceutical company accepted into the US FDA Emerging Technology Program.

Short descriptiontext

Triastek is a Chinese pharmaceutical 3D printing company that develops the proprietary MED® platform and five 3DμS® delivery technology platforms to create programmable oral drug products, serving global pharma companies through licensing, co-development, and technology partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNanjing, China
HQ citystring
Nanjing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D printed pharmaceuticals, pharmaceutical drug delivery, controlled release formulations, melt extrusion deposition, continuous pharmaceutical manufacturing
Industry2 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
3D Printed Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product License-out Partnerships
TypeLicensing Royalties
Description

Triastek develops proprietary 3D printed drug candidates through clinical development and out-licenses global commercialization rights to pharmaceutical partners. Revenue generated through upfront payments, milestone payments, and royalties on net sales.

triastek.com
2Technology Platform Services
TypeLicensing Royalties
Description

Providing MED® technology platform access to global pharmaceutical companies via research collaboration, platform co-development, and technology licensing. Partners include Eli Lilly, Boehringer Ingelheim, BioNTech, Merck/MilliporeSigma, and Sperogenix. Generates revenue through research fees, milestone payments, and technology access fees.

triastek.com
3Product Co-development
TypeProfessional Services
Description

Co-developing 3D printed pharmaceutical products with pharmaceutical partners using 505(b)(1) and 505(b)(2) pathways, sharing development costs and future revenues.

triastek.com
4Licensing Royalties from IP Portfolio
TypeLicensing Royalties
Description

Triastek holds 152 patent applications and 117 granted patents across 12 territories, constituting over 20% of global 3D printing pharmaceutical patent applications. IP licensing generates ongoing revenue.

triastek.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1MED®
Description

Melt Extrusion Deposition - Triastek's proprietary 3D printing pharmaceutical process that transforms delivery, development, and production of medicines through digital product development and continuous manufacturing.

triastek.com
+2 more records
Core offering1 text field

Triastek develops and manufactures proprietary 3D-printed pharmaceutical drug products using its MED® (Melt Extrusion Deposition) additive manufacturing technology, which produces solid oral dosage forms with programmable 3D geometric structures enabling precise control over drug release timing, location, and rate. The company commercializes via two B2B models: (1) Product License-out Partnerships, in which Triastek's IND-cleared drug candidates (D23, T20G, T24, T25, T26) are out-licensed to global pharma partners for commercialization, and (2) Technology Platform Partnerships, providing MED® platform access and co-development services to pharmaceutical companies like Eli Lilly, Boehringer Ingelheim, BioNTech, and Merck KGaA. Manufacturing is performed at a GMP-compliant 3D printing pharmaceutical continuous production line in Nanjing with 75 million tablets annual capacity.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • T19 achieves blood concentration peak in early morning hours matching circadian rhythm of rheumatoid arthritis symptoms, improving symptom relief vs. standard formulations.
+6 more records
Product overview1 text field

Triastek is a pharmaceutical technology company offering a platform-based approach centered on its proprietary MED® (Melt Extrusion Deposition) 3D printing technology. The core platform is complemented by five specialized 3D microstructure delivery technology platforms: 3DμS®-IT (intestine targeting), 3DμS®-MR (modified release), 3DμS®-GR (gastric retention), 3DμS®-SE (solubility enhancement), and 3DμS®-OM (oral macromolecules). The company also provides the 3DFbD® digital formulation development tool. Triastek's technology enables programmable precise control of drug release timing, location, and rate. The company operates two complementary business models: developing proprietary drug products (T19, T20, T20G, T21, T24, T25, T26, D23) internally for licensing out, and offering technology platform partnerships to global pharmaceutical companies. The manufacturing processes include MED® (standard), MED&MIM (melt extrusion with micro-injection molding for gastric retention), and MED&SSE (melt extrusion with semi-solid extrusion for peptides and macromolecules).

Product and service11 records
1MED® (Melt Extrusion Deposition) 3D Printing Process
CategoryCore Technology Platform
Description

Triastek's proprietary additive manufacturing technology platform that continuously converts powder feedstocks into softened/molten states followed by precise layer-by-layer deposition to produce solid dosage forms with designed 3D geometric structures. Operates at 25°C–250°C, handles 200+ pharmaceutical excipients and 1000+ compositions, uses fully automated continuous manufacturing with real-time PAT feedback control, and is sold/licensed to pharmaceutical partners via the Technology Platform Partnership model.

2T19 (Budesonide Delayed-Release Tablet)
CategoryDrug Product
Description

Triastek's first 3D printed drug product, a chronotherapeutic budesonide delayed-release tablet for rheumatoid arthritis. Taken at bedtime with delayed release for blood concentration peaks in early morning hours when RA symptoms are most acute. Developed using MED® 3D printing and the 3DμS®-MR modified release platform.

3T20 (Apixaban Cardiovascular Product)
CategoryDrug Product
Description

3D printed apixaban product for cardiovascular and clotting disorders developed using the 3DFbD® digital formulation method as a once-daily formulation. The second Triastek product to receive FDA IND clearance.

4T20G (Apixaban Gastroretentive Extended-Release Capsule)
CategoryDrug Product
Description

3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product for stroke prevention in atrial fibrillation (NVAF), DVT, PE, and VTE. Uses the MED&MIM process with 3DμS®-GR platform for once-daily dosing versus twice-daily for the reference listed drug.

5T21 (Colon-Targeted Tablet)
CategoryDrug Product
Description

Colon-targeted 3D printed drug product for the treatment of ulcerative colitis. Uses an enteric layer and delay layer protecting the drug core for precise delivery to the colon, with X-ray imaging verification of colon targeting achieved in first-in-human study.

6T24 (Ramelteon Dual-Release Tablet)
CategoryDrug Product
Description

Dual-release tablet for insomnia providing single dosing with dual precise timed-release addressing both sleep initiation and sleep maintenance difficulties. Built on the 3DμS®-MR modified release platform using MED® 3D printing.

7T25 (Octreotide Acetate Tablet)
CategoryDrug Product
Description

Oral peptide product for maintenance treatment of adult patients with acromegaly. First oral peptide candidate to enter clinical development. Uses the MED&SSE process and 3DμS®-OM dual-chamber delivery system to protect octreotide from gastric degradation and enable precise delivery to intended absorption sites.

8T26 (Itraconazole Tablet)
CategoryDrug Product
Description

3D printed solubility-enhancing antifungal product for treatment of mycoses. Built on the 3DμS®-SE delivery system combining amorphous solid dispersion with precision-engineered honeycomb microstructures to improve bioavailability of poorly soluble itraconazole, eliminating non-environmentally friendly organic solvents like dichloromethane.

9D23 (Budesonide Ileum Targeted Tablets)
CategoryDrug Product
Description

Ileum-targeted budesonide delayed-release tablet for the treatment of IgA nephropathy (IgAN). Uses MED® 3D printing and the 3DμS®-IT intestine targeting platform to precisely deliver budesonide to Peyer's lymph nodes in the ileum, reducing patient medication burden from 4 capsules of the originator to a single tablet design.

10MED® Technology Platform Partnership Service
CategoryTechnology Platform Service
Description

Technology platform service providing pharmaceutical companies access to Triastek's MED® 3D printing process, 3DFbD® digital formulation methodology, and 3DμS® delivery technology platforms via research collaboration, co-development, and technology licensing. Named partners include Eli Lilly, Boehringer Ingelheim, BioNTech, Merck KGaA, Siemens, and Sperogenix.

11Product License-out Partnership Service
CategoryLicensing Service
Description

Licensing service through which Triastek out-licenses its proprietary IND-cleared 3D printed drug candidates to global pharmaceutical companies for commercialization. Triastek retains IP rights; partners obtain commercialization rights in exchange for upfront fees, milestone payments, and royalties on net sales. Active licensed products include D23, T24, T20G, T25, and T26.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1BioNTech SE
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-07-23
Description

Research collaboration and platform technology license agreement to develop RNA therapeutics for oral delivery based on 3D printing technology. Aims to provide groundbreaking therapies to address unmet medical needs in easy-to-administer oral formulations. First announced July 2024.

triastek.com
2Boehringer Ingelheim China
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-03-17
Description

Collaboration to explore application of Triastek's MED® 3D printing technology in accelerating development of dosage forms for new chemical entities (NCE). Triastek deploys MED® technology to create multiple prototypes exploring different dose designs and drug release behaviors at speed, accelerating R&D cycles and increasing product development success rates. Boehringer Ingelheim showcased Triastek's 3D printed drug development prototype at CIIE 2023.

triastek.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-07-13
Description

Research collaboration to leverage 3D printing technology for precisely targeted and programmed release of drugs in specific regions of the GI tract. Project focuses on intestinal targeted release, studying excipient properties, process parameters for drug stability, and unique 3D structure dosage form designs for programmed release to improve bioavailability of orally administered drugs. Facilitated by Lilly China Innovation & Partnerships.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2022-03-03
Description

Strategic collaboration for digital transformation of the pharmaceutical industry. Combines Triastek's 3D printing and digital pharmaceutical technologies with Siemens' global leadership in automation and digitization. Collaboration areas include continuous manufacturing, paperless production, real-time product release, equipment and facility maintenance, digital twin technologies, and establishment of an intelligent pharmaceutical manufacturing center. Deepening strategic cooperation agreement signed at CIIE 2023.

5Merck KGaA (MilliporeSigma / SAFC Raw Materials)
Strategic tierModerateTypeStrategic or Co-development Partner
Description

Joint research project to demonstrate applicability of PVA solubility enhancement platform (Parteck® MXP excipient) for 3D printing using MED® technology. Focused on continuous printing of poorly soluble drugs using amorphous solid dispersions. Synergies between Triastek's MED® technology and MilliporeSigma's PVA solubility excipient demonstrated for fine-tuning release kinetics with designed structures.

triastek.com
Strategic tierModerateTypeStrategic or Co-development Partner
Description

Strategic partnership for innovative pharmaceutical product development using MED® 3D printing technology. Mentioned among Triastek's established strategic partnerships with global pharmaceutical companies including Eli Lilly, Merck, Boehringer Ingelheim, and Siemens.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Aprecia is the only FDA-approved 3D printed pharmaceutical company (Spritam/levetiracetam, approved 2015). Directly comparable as a pioneer in 3D printing pharmaceuticals with proprietary binder jetting technology. Most established competitor in Triastek's category.

TypeDirect peer
Description

UK-based 3D printing pharmaceutical company founded in 2018, specializing in personalized medicines and pharmaceutical 3D printing technologies. Directly comparable as a specialized 3D pharma company pursuing clinical and commercial applications of additive manufacturing for drug products.

3Laxxon Medical
TypeEmerging player
Description

Laxxon Medical is a US/Germany-based pharmaceutical technology company developing 3D printed pharmaceuticals with a focus on oral dosage forms. Comparable as an emerging 3D pharma player pursuing similar application areas (modified release, solubility enhancement) using additive manufacturing.

TypeEmerging player
Description

Craft Health is a Singapore/US-based 3D printed pharmaceutical company developing personalized medicines and 3D printed drug products. Comparable as an emerging 3D pharma player in the additive manufacturing pharmaceutical space.

TypeBroad incumbent
Description

Global pharmaceutical and life sciences company that has partnered with Triastek on solubility enhancement excipients (Parteck MXP) and has its own 3D printing pharmaceutical initiatives. Comparable as a broad incumbent with overlapping 3D pharma interests and as an existing Triastek partner.

TypeBroad incumbent
Description

Global pharmaceutical MNC that partnered with Triastek on intestinal-targeted 3D printed drug delivery. Comparable as a broad incumbent exploring 3D printing for oral drug delivery and an active Triastek partner.

TypeBroad incumbent
Description

Global biotechnology company that entered a research collaboration and platform technology license with Triastek for oral RNA therapeutics. Comparable as a leading biotech exploring 3D printed oral biologics delivery and an active Triastek partner.

8Boehringer Ingelheim
TypeBroad incumbent
Description

Global pharmaceutical company collaborating with Triastek on 3D printing for new chemical entity dosage form development. Comparable as a broad incumbent exploring 3D pharma applications and an active Triastek partner.

TypeBroad incumbent
Description

Global health technology and automation company partnering with Triastek on digital pharmaceutical manufacturing. Comparable as a broad incumbent collaborating on continuous manufacturing automation and digital transformation in pharmaceutical 3D printing.

TypeEmerging player
Description

Extend Biosciences is a US-based biotech developing delivery technologies for peptides and proteins, including oral and injectable sustained-release formulations. Comparable as an emerging player focused on challenging formulation/delivery problems similar to Triastek's 3DμS®-OM platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Triastek

3D Printed Pharmaceuticalstriastek.com

Triastek is a Chinese pharmaceutical 3D printing company that develops the proprietary MED® platform and five 3DμS® delivery technology platforms to create programmable oral drug products, serving global pharma companies through licensing, co-development, and technology partnerships.

What Triastek does

Triastek, Inc. is a privately held Chinese pharmaceutical technology company founded in July 2015 and headquartered in Nanjing, Jiangsu, with additional offices in Shanghai and a GMP-compliant production facility in Nanjing. The company developed and commercializes the proprietary Melt Extrusion Deposition (MED®) 3D printing process, an additive manufacturing technology that continuously converts powder feedstocks into softened or molten states and deposits them layer-by-layer to produce solid oral dosage forms with engineered 3D geometric structures. MED® operates across a 25–250°C temperature range, supports more than 200 pharmaceutical excipients and 1,000+ compositions, and integrates Process Analytical Technology (PAT) for real-time, per-tablet quality control. The platform is complemented by a family of five specialized 3D Microstructure delivery technology platforms (3DμS®-IT, -MR, -GR, -SE, -OM) and two hybrid processes (MED&MIM for gastric retention, MED&SSE for peptides), as well as the 3DFbD® digital formulation-by-design methodology.

The company operates a dual business model. In its Product Partnership model, Triastek internally develops proprietary 3D-printed drug candidates (T19, T20, T20G, T21, T24, T25, T26, D23) through FDA 505(b)(1)/(b)(2) and NMPA pathways and out-licenses global commercialization rights for upfront fees, development milestones, and royalties. In its Technology Platform Partnership model, it provides MED® platform access, research collaboration, and co-development services to global pharmaceutical companies; named partners include Eli Lilly, Boehringer Ingelheim, BioNTech, Merck KGaA (MilliporeSigma), Siemens, and Sperogenix. Revenue is generated through research fees, milestone payments, technology access fees, and licensing royalties. The company holds 152 patent applications and 117 granted patents across 12 territories, representing more than 20% of global 3D printing pharmaceutical patent applications, and was the first Chinese pharmaceutical company accepted into the US FDA Emerging Technology Program.

Triastek firmographics

Firmographics
Name
Triastek
Legal name
Triastek, Inc.
Website
https://triastek.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Triastek is a Chinese pharmaceutical 3D printing company that develops the proprietary MED® platform and five 3DμS® delivery technology platforms to create programmable oral drug products, serving global pharma companies through licensing, co-development, and technology partnerships.
Ownership category
akta.pro rank

Triastek industry classification

Industry
Product category
3D Printed Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • 3D printed pharmaceuticals
  • Pharmaceutical drug delivery
  • Controlled release formulations
  • Melt extrusion deposition
  • Continuous pharmaceutical manufacturing

Where Triastek is headquartered

Location

Headquarters

HQ city
Nanjing
HQ country
China
HQ region
Asia

Offices3 records

Markets served

Triastek business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Product License-out Partnerships: Triastek develops proprietary 3D printed drug candidates through clinical development and out-licenses global commercialization rights to pharmaceutical partners. Revenue generated through upfront payments, milestone payments, and royalties on net sales.
  2. Technology Platform Services: Providing MED® technology platform access to global pharmaceutical companies via research collaboration, platform co-development, and technology licensing. Partners include Eli Lilly, Boehringer Ingelheim, BioNTech, Merck/MilliporeSigma, and Sperogenix. Generates revenue through research fees, milestone payments, and technology access fees.
  3. Product Co-development: Co-developing 3D printed pharmaceutical products with pharmaceutical partners using 505(b)(1) and 505(b)(2) pathways, sharing development costs and future revenues.
  4. Licensing Royalties from IP Portfolio: Triastek holds 152 patent applications and 117 granted patents across 12 territories, constituting over 20% of global 3D printing pharmaceutical patent applications. IP licensing generates ongoing revenue.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Triastek product offering

Product offering

Core offering

Triastek develops and manufactures proprietary 3D-printed pharmaceutical drug products using its MED® (Melt Extrusion Deposition) additive manufacturing technology, which produces solid oral dosage forms with programmable 3D geometric structures enabling precise control over drug release timing, location, and rate. The company commercializes via two B2B models: (1) Product License-out Partnerships, in which Triastek's IND-cleared drug candidates (D23, T20G, T24, T25, T26) are out-licensed to global pharma partners for commercialization, and (2) Technology Platform Partnerships, providing MED® platform access and co-development services to pharmaceutical companies like Eli Lilly, Boehringer Ingelheim, BioNTech, and Merck KGaA. Manufacturing is performed at a GMP-compliant 3D printing pharmaceutical continuous production line in Nanjing with 75 million tablets annual capacity.

Product overview

Triastek is a pharmaceutical technology company offering a platform-based approach centered on its proprietary MED® (Melt Extrusion Deposition) 3D printing technology. The core platform is complemented by five specialized 3D microstructure delivery technology platforms: 3DμS®-IT (intestine targeting), 3DμS®-MR (modified release), 3DμS®-GR (gastric retention), 3DμS®-SE (solubility enhancement), and 3DμS®-OM (oral macromolecules). The company also provides the 3DFbD® digital formulation development tool. Triastek's technology enables programmable precise control of drug release timing, location, and rate. The company operates two complementary business models: developing proprietary drug products (T19, T20, T20G, T21, T24, T25, T26, D23) internally for licensing out, and offering technology platform partnerships to global pharmaceutical companies. The manufacturing processes include MED® (standard), MED&MIM (melt extrusion with micro-injection molding for gastric retention), and MED&SSE (melt extrusion with semi-solid extrusion for peptides and macromolecules).

Differentiator

Problem solved

Functional benefit

Brands

  • MED®: Melt Extrusion Deposition - Triastek's proprietary 3D printing pharmaceutical process that transforms delivery, development, and production of medicines through digital product development and continuous manufacturing.
  • 3DμS®
  • 3DFbD®

Products and services

  • MED® (Melt Extrusion Deposition) 3D Printing Process Triastek's proprietary additive manufacturing technology platform that continuously converts powder feedstocks into softened/molten states followed by precise layer-by-layer deposition to produce solid dosage forms with designed 3D geometric structures. Operates at 25°C–250°C, handles 200+ pharmaceutical excipients and 1000+ compositions, uses fully automated continuous manufacturing with real-time PAT feedback control, and is sold/licensed to pharmaceutical partners via the Technology Platform Partnership model.
  • T19 (Budesonide Delayed-Release Tablet) Triastek's first 3D printed drug product, a chronotherapeutic budesonide delayed-release tablet for rheumatoid arthritis. Taken at bedtime with delayed release for blood concentration peaks in early morning hours when RA symptoms are most acute. Developed using MED® 3D printing and the 3DμS®-MR modified release platform.
  • T20 (Apixaban Cardiovascular Product) 3D printed apixaban product for cardiovascular and clotting disorders developed using the 3DFbD® digital formulation method as a once-daily formulation. The second Triastek product to receive FDA IND clearance.
  • T20G (Apixaban Gastroretentive Extended-Release Capsule) 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product for stroke prevention in atrial fibrillation (NVAF), DVT, PE, and VTE. Uses the MED&MIM process with 3DμS®-GR platform for once-daily dosing versus twice-daily for the reference listed drug.
  • T21 (Colon-Targeted Tablet) Colon-targeted 3D printed drug product for the treatment of ulcerative colitis. Uses an enteric layer and delay layer protecting the drug core for precise delivery to the colon, with X-ray imaging verification of colon targeting achieved in first-in-human study.
  • T24 (Ramelteon Dual-Release Tablet) Dual-release tablet for insomnia providing single dosing with dual precise timed-release addressing both sleep initiation and sleep maintenance difficulties. Built on the 3DμS®-MR modified release platform using MED® 3D printing.
  • T25 (Octreotide Acetate Tablet) Oral peptide product for maintenance treatment of adult patients with acromegaly. First oral peptide candidate to enter clinical development. Uses the MED&SSE process and 3DμS®-OM dual-chamber delivery system to protect octreotide from gastric degradation and enable precise delivery to intended absorption sites.
  • T26 (Itraconazole Tablet) 3D printed solubility-enhancing antifungal product for treatment of mycoses. Built on the 3DμS®-SE delivery system combining amorphous solid dispersion with precision-engineered honeycomb microstructures to improve bioavailability of poorly soluble itraconazole, eliminating non-environmentally friendly organic solvents like dichloromethane.
  • D23 (Budesonide Ileum Targeted Tablets) Ileum-targeted budesonide delayed-release tablet for the treatment of IgA nephropathy (IgAN). Uses MED® 3D printing and the 3DμS®-IT intestine targeting platform to precisely deliver budesonide to Peyer's lymph nodes in the ileum, reducing patient medication burden from 4 capsules of the originator to a single tablet design.
  • MED® Technology Platform Partnership Service Technology platform service providing pharmaceutical companies access to Triastek's MED® 3D printing process, 3DFbD® digital formulation methodology, and 3DμS® delivery technology platforms via research collaboration, co-development, and technology licensing. Named partners include Eli Lilly, Boehringer Ingelheim, BioNTech, Merck KGaA, Siemens, and Sperogenix.
  • Product License-out Partnership Service Licensing service through which Triastek out-licenses its proprietary IND-cleared 3D printed drug candidates to global pharmaceutical companies for commercialization. Triastek retains IP rights; partners obtain commercialization rights in exchange for upfront fees, milestone payments, and royalties on net sales. Active licensed products include D23, T24, T20G, T25, and T26.

Quantifiable outcome

  • T19 achieves blood concentration peak in early morning hours matching circadian rhythm of rheumatoid arthritis symptoms, improving symptom relief vs. standard formulations.
  • +6 more outcomes

Companies that use Triastek

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Triastek technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature11 records

Triastek partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major and moderate.

  • BioNTech SEmajorStrategic or Co-development Partner · 23 July 2024Research collaboration and platform technology license agreement to develop RNA therapeutics for oral delivery based on 3D printing technology. Aims to provide groundbreaking therapies to address unmet medical needs in easy-to-administer oral formulations. First announced July 2024.
  • Boehringer Ingelheim ChinamajorStrategic or Co-development Partner · 17 March 2023Collaboration to explore application of Triastek's MED® 3D printing technology in accelerating development of dosage forms for new chemical entities (NCE). Triastek deploys MED® technology to create multiple prototypes exploring different dose designs and drug release behaviors at speed, accelerating R&D cycles and increasing product development success rates. Boehringer Ingelheim showcased Triastek's 3D printed drug development prototype at CIIE 2023.
  • Eli Lilly and CompanymajorStrategic or Co-development Partner · 13 July 2022Research collaboration to leverage 3D printing technology for precisely targeted and programmed release of drugs in specific regions of the GI tract. Project focuses on intestinal targeted release, studying excipient properties, process parameters for drug stability, and unique 3D structure dosage form designs for programmed release to improve bioavailability of orally administered drugs. Facilitated by Lilly China Innovation & Partnerships.
  • Siemens Ltd., ChinamajorTechnology or Integration · 3 March 2022Strategic collaboration for digital transformation of the pharmaceutical industry. Combines Triastek's 3D printing and digital pharmaceutical technologies with Siemens' global leadership in automation and digitization. Collaboration areas include continuous manufacturing, paperless production, real-time product release, equipment and facility maintenance, digital twin technologies, and establishment of an intelligent pharmaceutical manufacturing center. Deepening strategic cooperation agreement signed at CIIE 2023.
  • Merck KGaA (MilliporeSigma / SAFC Raw Materials)moderateStrategic or Co-development PartnerJoint research project to demonstrate applicability of PVA solubility enhancement platform (Parteck® MXP excipient) for 3D printing using MED® technology. Focused on continuous printing of poorly soluble drugs using amorphous solid dispersions. Synergies between Triastek's MED® technology and MilliporeSigma's PVA solubility excipient demonstrated for fine-tuning release kinetics with designed structures.
  • SperogenixmoderateStrategic or Co-development PartnerStrategic partnership for innovative pharmaceutical product development using MED® 3D printing technology. Mentioned among Triastek's established strategic partnerships with global pharmaceutical companies including Eli Lilly, Merck, Boehringer Ingelheim, and Siemens.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Triastek competitors and assessment

Company assessment

Direct peers

  • Aprecia Pharmaceuticals: Aprecia is the only FDA-approved 3D printed pharmaceutical company (Spritam/levetiracetam, approved 2015). Directly comparable as a pioneer in 3D printing pharmaceuticals with proprietary binder jetting technology. Most established competitor in Triastek's category.
  • FabRx: UK-based 3D printing pharmaceutical company founded in 2018, specializing in personalized medicines and pharmaceutical 3D printing technologies. Directly comparable as a specialized 3D pharma company pursuing clinical and commercial applications of additive manufacturing for drug products.

Emerging players

  • Laxxon Medical: Laxxon Medical is a US/Germany-based pharmaceutical technology company developing 3D printed pharmaceuticals with a focus on oral dosage forms. Comparable as an emerging 3D pharma player pursuing similar application areas (modified release, solubility enhancement) using additive manufacturing.
  • Craft Health: Craft Health is a Singapore/US-based 3D printed pharmaceutical company developing personalized medicines and 3D printed drug products. Comparable as an emerging 3D pharma player in the additive manufacturing pharmaceutical space.
  • Extend Biosciences: Extend Biosciences is a US-based biotech developing delivery technologies for peptides and proteins, including oral and injectable sustained-release formulations. Comparable as an emerging player focused on challenging formulation/delivery problems similar to Triastek's 3DμS®-OM platform.

Broad incumbents

  • Merck KGaA (MilliporeSigma): Global pharmaceutical and life sciences company that has partnered with Triastek on solubility enhancement excipients (Parteck MXP) and has its own 3D printing pharmaceutical initiatives. Comparable as a broad incumbent with overlapping 3D pharma interests and as an existing Triastek partner.
  • Eli Lilly: Global pharmaceutical MNC that partnered with Triastek on intestinal-targeted 3D printed drug delivery. Comparable as a broad incumbent exploring 3D printing for oral drug delivery and an active Triastek partner.
  • BioNTech: Global biotechnology company that entered a research collaboration and platform technology license with Triastek for oral RNA therapeutics. Comparable as a leading biotech exploring 3D printed oral biologics delivery and an active Triastek partner.
  • Boehringer Ingelheim: Global pharmaceutical company collaborating with Triastek on 3D printing for new chemical entity dosage form development. Comparable as a broad incumbent exploring 3D pharma applications and an active Triastek partner.
  • Siemens Healthineers: Global health technology and automation company partnering with Triastek on digital pharmaceutical manufacturing. Comparable as a broad incumbent collaborating on continuous manufacturing automation and digital transformation in pharmaceutical 3D printing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Triastek social profiles

Digital presence

Triastek compliance and trust

Trust signal

Compliance1 record

Triastek financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Triastek leadership team

Management profile

Number of profiles

Profiles8 records

Triastek funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Triastek M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triastek

What does Triastek do?

Triastek develops and manufactures proprietary 3D-printed pharmaceutical drug products using its MED® (Melt Extrusion Deposition) additive manufacturing technology, which produces solid oral dosage forms with programmable 3D geometric structures enabling precise control over drug release timing, location, and rate. The company commercializes via two B2B models: (1) Product License-out Partnerships, in which Triastek's IND-cleared drug candidates (D23, T20G, T24, T25, T26) are out-licensed to global pharma partners for commercialization, and (2) Technology Platform Partnerships, providing MED® platform access and co-development services to pharmaceutical companies like Eli Lilly, Boehringer Ingelheim, BioNTech, and Merck KGaA. Manufacturing is performed at a GMP-compliant 3D printing pharmaceutical continuous production line in Nanjing with 75 million tablets annual capacity.

Is Triastek a public or private company?

Triastek is a private company. It is classified as venture growth investor backed and is currently operating.

When was Triastek founded?

Triastek was founded in 2015. It employs 11 to 50 people.

Where is Triastek based?

Triastek is headquartered in Nanjing, China, in the Asia region.

How does Triastek make money?

Four revenue lines are on record. Product License-out Partnerships are the primary driver. The others are technology Platform Services, product Co-development and licensing Royalties from IP Portfolio.

Who are Triastek's main competitors?

Direct peers on record are Aprecia Pharmaceuticals and FabRx. Emerging players are Laxxon Medical, Craft Health and Extend Biosciences. Broad incumbents are Merck KGaA (MilliporeSigma), Eli Lilly, BioNTech, Boehringer Ingelheim and Siemens Healthineers.

Does Triastek have an API?

No public API is recorded for Triastek.

What industry is Triastek in?

Triastek's product category is 3D Printed Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PatsnapContinuous manufacturing vs batch processing in pharmaA patent intelligence analysis of over 50 records across multiple jurisdictions maps the technical mechanisms, key IP holders, and quality control innovations driving the transition from batch to continuous pharmaceutical solid dosage manufacturing. The report identifies six dominant organizations holding strategically significant IP positions: SmithKline Beecham/GlaxoSmithKline (14+ jurisdictions), GEA Pharma Systems, Warner Lambert, MIT, Triastek Inc., and BASF/Rutgers. Innovation progression from 2003 to 2025 shows the field maturing from foundational granulation/dispensing architectures to integrated tablet compression with inline analytics, multi-dosage flexible systems, and pharmaceutical additive manufacturing.Fortunebusinessinsights3D Printed Drugs Market Size, Share, Growth Report, 2034The global 3D printed drugs market was valued at USD 140.6 billion in 2025 and is projected to reach USD 496.95 billion by 2034, growing at a CAGR of 15.06% during the forecast period 2026–2034. Key market drivers include rising demand for personalized medicine, FDA approval of products such as Spritam (levetiracetam), and technological advances in 3D printing techniques including inkjet printing, selective laser sintering, and melt extrusion deposition. North America currently leads the market, while the Asia-Pacific region is expected to experience the fastest growth, with key players including Aprecia Pharmaceutical, TRIASTEK, and FabRx Ltd.GlobeNewswireTriastek's 3D Printed Gastric Retention Product T22 Receives FDA Clearance of IND ApplicationTriastek received FDA clearance to proceed with its 3D-printed gastric retention product T22, the first of its kind. The product, for pulmonary arterial hypertension, reduces dosing from three times daily to once daily. The company plans to initiate clinical studies.FinSMEsTriastek Closes USD 20.4M Pre-C Funding RoundTriastek, a Nanjing-based 3D printing pharmaceutical company, raised $20.4M in pre-C funding led by Guoxin Investment. The funds will accelerate innovation in drug development and manufacturing, and the company has partnerships with Eli Lilly, Merck, and others.GlobeNewswireTriastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and ProductsTriastek announced the completion of a USD 20.4 million Pre-C funding round led by Guoxin Investment, with participation from Goldmine Multi-family Office and Shanghai Tofflon Science and Technology Co. Ltd. The company intends to use the capital to accelerate the commercialization of its proprietary Melt Extrusion Deposition (MED) 3D printing pharmaceutical technology. Triastek currently holds strategic partnerships with major global pharmaceutical firms including Eli Lilly, Merck KGaA, and Boehringer Ingelheim.BioSpaceTriastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and ProductsTriastek, Inc. completed a USD 20.4 million Pre-C financing round led by Guoxin Investment with participation from Goldmine Multi-family Office and Shanghai Tofflon Science and Technology Co. Ltd. The company intends to use the funds to accelerate the commercialization of its proprietary Melt Extrusion Deposition (MED®) 3D printing pharmaceutical technology. Triastek currently holds strategic partnerships with major global pharmaceutical firms including Eli Lilly, Merck KGaA, and Boehringer Ingelheim.BioWorldTriastek taps into technology for unique pipeline developmentTriastek Inc. is developing a pipeline for rheumatoid arthritis, clotting disorders, ulcerative colitis, and pulmonary hypertension using 3D printing technology. Its products T-19, T-20, and T-21 have received FDA IND approval, and the technology was validated through a partnership with Boehringer Ingelheim GmbH.PR NewswireTriastek erhält FDA-IND-Zulassung für 3D-gedrucktes Medikament zur Behandlung von Colitis ulcerosaTriastek received an Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to begin clinical trials for T21, a 3D-printed drug designed to treat ulcerative colitis. This marks the company's third IND approval, following similar clearances for products targeting rheumatoid arthritis and cardiovascular disorders. The approval allows Triastek to test its proprietary Melt Extrusion Deposition technology for targeted drug delivery in the colon.PR NewswireTriastek recibe autorización IND de la FDA para la medicina impresa 3D para la colitis ulcerosaTriastek, Inc., a pharmaceutical company specializing in 3D printed drug manufacturing using its Melt Extrusion Deposition (MED®) technology, received FDA Investigational New Drug (IND) authorization to initiate clinical trials for T21, a 3D printed drug designed as a targeted treatment for ulcerative colitis. T21 uses a unique 3D dosage form design to deliver drugs directly to the colon segment of the gastrointestinal tract, enabling a lower drug dose compared to the reference drug while reducing systemic drug exposure. This marks Triastek's third FDA IND approval, following prior authorizations for T19 (rheumatoid arthritis) and T20 (cardiovascular and coagulation disorders), demonstrating the scalability of its MED® platform across multiple therapeutic areas.PR NewswireTriastek reçoit l'autorisation de la FDA pour un médicament imprimé en 3D destiné au traitement de la colite ulcéreuseTriastek, Inc. received FDA authorization for its Investigational New Drug (IND) application to begin clinical trials for T21, a 3D-printed drug designed for colon-targeted delivery to treat ulcerative colitis. The drug utilizes Triastek's proprietary Melt Extrusion Deposition (MED®) technology, enabling targeted release in the colon with potentially lower doses than conventional reference drugs. This marks Triastek's third FDA IND approval, following previous authorizations for T19 (rheumatoid arthritis) and T20 (cardiovascular and coagulation disorders).